Within-Host Evolution Results in Antigenically Distinct GII.4 Noroviruses

Abstract

Genogroup II, genotype 4 (GII.4) noroviruses are known to rapidly evolve, with the emergence of a new primary strain every 2 to 4 years as herd immunity to the previously circulating strain is overcome. Because viral genetic diversity is higher in chronic than in acute infection, chronically infected immunocompromised people have been hypothesized to be a potential source for new epidemic GII.4 strains. However, while some capsid protein residues are under positive selection and undergo patterned changes in sequence variation over time, the relationships between genetic variation and antigenic variation remains unknown. Based on previously published GII.4 strains from a chronically infected individual, we synthetically reconstructed virus-like particles (VLPs) representing early and late isolates from a small-bowel transplant patient chronically infected with norovirus, as well as the parental GII.4-2006b strain. We demonstrate that intrahost GII.4 evolution results in the emergence of antigenically distinct strains over time, comparable to the variation noted between the chronologically predominant GII.4 strains GII.4-2006b and GII.4-2009. Our data suggest that in some individuals the evolution that occurs during a chronic norovirus infection overlaps with changing antigenic epitopes that are associated with successive outbreak strains and may select for isolates that are potentially able to escape herd immunity from earlier isolates. IMPORTANCENoroviruses are agents of gastrointestinal illness, infecting an estimated 21 million people per year in the United States alone. In healthy individuals, symptomatic infection typically resolves within 24 to 48 h. However, symptoms may persist for years in immunocompromised individuals, and development of successful treatments for these patients is a continuing challenge. This work is relevant to the design of successful norovirus therapeutics for chronically infected patients; provides support for previous assertions that chronically infected individuals may serve as reservoirs for new, antigenically unique emergent strains; and furthers our understanding of genogroup II, genotype 4 (GII.4) norovirus immune-driven molecular evolution.

Mapping Broadly Reactive Norovirus Genogroup I and II Monoclonal Antibodies

“…However, it is currently approved for use only in outbreak settings, because it lacks sensitivity (49)(50)(51)(52). The increasing evidence that noroviruses are undergoing antigenic variation highlights the need for diagnostic assays that detect broadly cross-reactive epitopes (53)(54)(55). We have identified a broadly cross-reactive epitope in the C-terminal P1 domain that is surface exposed; the majority of these residues are dissimilar between human norovirus strains, suggesting that this region may remain invariant while other domains of the virus are undergoing antigenic variation.…”

Prevalence and molecular characterization of human noroviruses and sapoviruses in Ethiopia

“…Several NoV pandemics associated with GII.4 have occurred every 2 to 3 years [67][68][69][70][71][72][73][74]. The recent or new pandemic isolate GII.4 2012 Sydney, which was first identified in March 2012 in Australia [75], is currently the dominant GII.4 variant identified in NoVassociated gastroenteritis outbreaks worldwide [75].…”

Genome plasticity of triple-reassortant H1N1 influenza A virus during infection of vaccinated pigs

“…Multiple studies have evaluated the intra-host diversity of RNA viruses overtime (Debbink et al, 2014;Salemi, 2013;Tu et al, 2013). In IAVs, this research has focused on HA Murcia et al, 2010Murcia et al, , 2013.…”